NASDAQ:LEGN
Legend Biotech Corporation Stock News
$43.98
+0.240 (+0.549%)
At Close: May 01, 2024
Why Legend Biotech (LEGN) Stock Might be a Great Pick
09:50am, Monday, 08'th Apr 2024
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Legend Biotech Corporation (LEGN) Q4 2023 Earnings Call Transcript
12:09pm, Monday, 11'th Mar 2024
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2023 Earnings Conference March 11, 2024 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief E
Next-gen leaders: The biotech stock set to soar on groundbreaking innovation
08:31am, Monday, 11'th Mar 2024
The biotech industry is evolving rapidly, with 2024 poised to be a year of significant advancements and opportunities. Amidst an uncertain macroeconomic environment, the biotech sector is gaining mome
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
08:36am, Friday, 08'th Mar 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
09:10am, Tuesday, 23'rd Jan 2024
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
09:46am, Wednesday, 29'th Nov 2023
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
09:46am, Monday, 20'th Nov 2023
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q results
07:18am, Monday, 20'th Nov 2023
Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
12:02pm, Tuesday, 14'th Nov 2023
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
08:16am, Thursday, 09'th Nov 2023
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Legend Biotech: Working On Supply Issues
08:10pm, Monday, 21'st Aug 2023
Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal
Why Earnings Season Could Be Great for Legend Biotech (LEGN)
10:09am, Monday, 14'th Aug 2023
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
08:39am, Monday, 14'th Aug 2023
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
Top 5 Stocks Set to Beat on Earnings Next Week
09:15am, Thursday, 10'th Aug 2023
We have narrowed our search to five stocks that are set to declare earnings results next week. These are: LEGN, TJX, WMT, ONON, BILL.
3 Biotech Stocks That Analysts Are Drooling Over
06:57pm, Monday, 07'th Aug 2023
With everyone being an expert these days, the concept of top analyst biotech picks might seem suspect at first glance. While we depend on Wall Street's spectrum of expert guidance to establish a frame
